Skip to main content
MRVI logo

MRVI · Maravai Lifesciences Holdings, Inc.

Track MRVI — free
$7.45 +0.07 (+0.95%)
Market Cap
$1.92B
Shares
259.94M
Volume · Nov 18 1.41M Avg daily vol (3M) 3.19M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.38 Open$7.28 Day$7.21–7.54 52W close$2.83–9.00 Avg vol 30d2.2M Short int14.1M · 5.4% of shares · 6.8d Short vol46% Last earningsNov 4, 2026 DataNov 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 17
Investor event
Third-quarter mRNA revenue up 28% as enterprise sales grow 10%

Maravai Lifesciences reported third-quarter revenue growth of 10%, with mRNA up 28% and Cygnus up 8%. Management said the $14 million and change in first-quarter COVID-related clean cap revenue should be kept out of guidance.

3 source passages
In the third quarter, we grew our revenue enterprise by 10%, but mRNA itself grew 28%, and Cygnus had 8% growth. $14 million and change in the first quarter. We are encouraging everybody to take that out of the guide, and that's how we are thinking about it when we talk about that in February, is keep that outside. Open the document at this passage
Nov 12
Investor event
TriLink growth supports path to 35% EBITDA margin

Marvai Life Sciences expects TriLink to drive long-term growth, with just over 50 GMP customers and mRNA programs projected at $5 to $50 million per year at peak; management targets a 35% EBITDA margin as revenues scale.

6 source passages
Marvai Life Sciences is a leading provider of critical technologies and products that enable the development and manufacturing of life-changing therapeutics, vaccines, and diagnostics So TriLink, again, is the flagship that will carry the long-term high-growth opportunity for the company, especially as commercial revenue starts to flow in. It's critical to point out here that our target for this year was to get 50, you know, to onboard 10 new GMP customers, which we exceeded, and we're now at just over 50 GMP customers. And then once you get to the commercial stage, you're now significantly scaling clean cap, and you're also getting the GMP opportunity with Mottail and GMP enzymes, and we think this is a $5 to a $50 million per program opportunity per year at peak What do you think the chances are that you can return to something like 35% or 40% EBITDA margins? Yeah, that is personally my objective is I'd love to get back to that 35% range. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-Month Revenue Rose 20.1%, Gross Profit Rose 233.6%

Maravai LifeSciences Holdings, Inc. reported nine-month revenue of $163.1 million, up 20.1%, while gross profit reached 70,543 in thousands, up 233.6%.

Revenue $45.85M ▲ 10.1% Net loss $13.84M Diluted EPS -$0.09
Read from the MD&A section
4 source passages
Unless otherwise noted or the context otherwise requires, references in this Quarterly Report on Form 10-Q to “we,” “us” or “our” refer to Maravai LifeSciences Holdings, Inc. and its subsidiaries. We generated revenue of $45.9 million and $163.1 million for the three and nine months ended September 30, 2026 and $41.6 million and $135.9 million for the three and nine months ended September 30, 2025, respectively. Total revenue increased 20.1% from the nine months ended September 30, 2025 compared to the nine months ended September 30, 2026. Gross profit | 70,543 | 21,148 | 233.6% Open the document at this passage
Nov 4
Earnings call
Raises 2026 outlook after Q3 revenue and EBITDA improvement

Maravai reported third-quarter revenue of $45.9 million and adjusted EBITDA of $5.8 million, raising its 2026 revenue guidance to $212 million to $216 million and adjusted EBITDA guidance to $40 million to $42 million.

5 source passages
Hello, and welcome, everyone, joining today's Maravai Life Sciences Q3 2026 Results Earnings Call. During the quarter, we generated revenue of $45.9 million, representing 10% year-over-year growth. Adjusted EBITDA, a non-GAAP measure, was $5.8 million for Q3, improving by $16.6 million year-over-year. Based on our Q3 results and our visibility into Q4, we are raising our expected 2026 revenue range to $212 million to $216 million, up from the prior range of $205 million to $215 million, or up $4 million at the midpoint. We're also raising our full-year adjusted EBITDA guidance to $40 million to $42 million, up $7 million at the midpoint from prior range of $33 to $35 million. Open the document at this passage
Nov 4
Current report 8-K
Revenue rises 10%, 2026 guidance lifted

Maravai LifeSciences Holdings, Inc. reported third-quarter revenue of $45.9 million, up 10% from prior year, and raised 2026 revenue guidance to $212.0 million to $216.0 million. Adjusted EBITDA was $5.8 million; full-year guidance increased to $40.0 million to $42.0 million.

4 source passages
Third quarter 2026 total revenue up 10% from prior year Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) Quarterly revenue of $45.9 million, Net loss of $(24.0) million, and Adjusted EBITDA of $5.8 million; Full year 2026 revenue guidance range increased to $212.0 million to $216.0 million; Adjusted EBITDA guidance raised to $40.0 million to $42.0 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$213.00M
Trailing 12 months
Net income (TTM)
−$65.67M
Trailing 12 months
Revenue growth YoY
+10.1%
Year over year
Operating margin
-45.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$74.16M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.0%
Year over year · more shares
Price change (1Y)
+103.9%
Trailing year
Short interest
5.4%
Latest settlement · 6.8 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. Maravai posted Q2 revenue of $51.4M (up 9% YoY) and raised full-year adjusted EBITDA guidance to $33–$35M on stronger TriLink growth, but maintained its revenue range, posted a $(21.6)M GAAP net loss that included a $3.0M loss on debt extinguishment, and flagged lumpiness in CDMO and large GMP orders that creates back-half uncertainty.

Bullish
  • + Full-year 2026 adjusted EBITDA guidance raised to $33M–$35M from $30M–$32M on margin expansion.
  • + TriLink added a record 67 new Discovery mRNA customers in Q2 and e-commerce delivered record quarterly revenue.
  • + ModTail has reached more than 125 active customers within a year of launch and is being extended into GMP-grade.
  • + Debt was refinanced in June, reducing borrowings to ~$150M with maturities extended to 2032.
Bearish
  • − Full-year revenue guidance was maintained at $205M–$215M rather than raised, citing lumpiness in CDMO and large GMP orders.
  • − TriLink CDMO revenue declined year-over-year in Q2.
  • − Management flagged that Q3 is inherently a lower revenue quarter and that large multi-million dollar orders can shift between quarters.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +34%
above
Price vs 50-day avg −0%
below
RSI (14) 48
neutral
MACD trend Negative
52-week position 74%
mid-range
Momentum
relative strength
Strong
1-month return −3%
trailing
6-month return +54%
trailing
YTD return +127%
this year
Relative strength +57%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.41% of shares out · ▲ +5.3% MoM · 6.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
204 holders — mid 3-yr range
Squeeze score 73
high risk · 0–100
Fundamentals
Weak
Revenue growth −28%
Y/Y
Gross margin 18%
contracting
EPS growth +14%
Y/Y
Free cash flow $-70.7M
Balance sheet $74.9M
net debt
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −30%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the Earnings Call filed Aug 6, 2026
2026
Expected 2026 revenue range Maintained $205M – $215M
May 7, 2026 $205M – $215M changed to Aug 6, 2026 $205M – $215M
prior FY $185.74M midpoint +13.1% Y/Y
full-year 2026
Adjusted EBITDA Non-GAAP Raised $33M – $35M
May 7, 2026 $30M – $32M changed to Aug 6, 2026 $33M – $35M
Previous outlook earlier release · from the Earnings Call filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

COVID-19 revenue · 2026 $10M – $20M
Guided vs delivered · last 4 settled
Revenue full year 2025
guided $185M
$185.74M Beat +0.4%
Total revenue full year 2023
guided $275M – $285M
$288.95M Beat +3.2%
Total revenue full year 2022
guided $880M – $890M
$883M In line
Total revenue 2021 full-year
guided $770M – $780M
$799.24M Beat +3.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+34% Bullish
Price vs 50-day avg
−0% Neutral
RSI (14)
48 Neutral
MACD trend
Negative Bearish
52-week position
74% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +52 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.41% of shares out · ▲ +5.3% MoM · 6.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
204 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $7 · 74% Range high $9
vs 200-day avg +34% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $29M six months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MRVI
Maravai Lifesciences Holdings, Inc.
this stock
$1.92B +127.1% -28.3% — 5.4%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
204
% held
55.9%
Net QoQ
+5.0M sh
Top holder
GTCR LLC
Held Float
View
Held by Funds
Fund positions
173
View
Short & Settlement
Short Interest Rising
Shares short
14.1M
Days to cover
6.8d
Change
+705.0K sh
View
Short Volume
Short vol %
46%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
87
Value
$736
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
35.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Apr 10, 2023
View
Financials
Financials
Revenue (FY)
$185.7M
Net income (FY)
$-130.8M
EPS diluted
$-0.90
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
16

Maravai Lifesciences reported third-quarter revenue growth of 10%, with mRNA up 28% and Cygnus up 8%. Management said the $14 million and change in first-quarter COVID-related clean cap revenue should be kept out of guidance.

View
Proposed Sales
Value
$127.5K
Shares
25.0K
Filed
Jun 10, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Maravai LifeSciences Reports Thir…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
MRVI -4.2% -2.5% +53.8% -5.5% +127.1%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -0.3% +3.0% +57.2% -2.1% +120.0%
Key facts CIK 1823239 CUSIP 56600D107 13F (30d) 217 filings 198 filers Visit website Investor relations